By subject
Start with the question.
10 subjects, eight compound classes and two about the market itself. Each one answers the question plainly first, then hands you the evidence underneath it.
The incretin classGLP-1, GIP, the pivotal trial numbers, and where research material sits against approved drugs.5 articlesRepair and recoveryKPV, thymosin beta-4, TB-500 and BPC-157: a real preclinical literature and a missing clinical one.3 articlesThe growth-hormone axisSecretagogues, GHRH analogues and IGF-1: one approved drug, one real human dataset, and a family of models.3 articlesLongevity and cellularNAD+ precursors, mitochondrial peptides and the telomere compounds, tiered by how much human data exists.3 articlesSkin and appearanceCopper peptides have fifty years of dermatology behind them. The tanning compounds have no approval anywhere.2 articlesCognitive and sleepDSIP has no established mechanism. Semax and Selank are registered medicines in one country and unknown elsewhere.2 articlesSexual healthOxytocin, kisspeptin and PT-141: one long-approved hormone, one master switch, and one molecule with two names.4 articlesImmuneThymosin alpha-1, a licensed medicine in some countries and not in the United States, and why it is not thymosin beta-4.4 articlesVerificationWhat a complete certificate contains, how purity is measured, and what “third-party tested” does not mean.6 articlesRegulation and legalityApproved drug, unapproved new drug, compounding bulk substance, research material: four statuses, one word.6 articles
Or browse everything we’ve published →
For research use only · Not for human or veterinary use · No compound discussed here is FDA-approved for any indication